+

WO1997019113A3 - Anticuerpos monoclonales antiidiotipos (ab2) y sus usos - Google Patents

Anticuerpos monoclonales antiidiotipos (ab2) y sus usos Download PDF

Info

Publication number
WO1997019113A3
WO1997019113A3 PCT/CU1996/000003 CU9600003W WO9719113A3 WO 1997019113 A3 WO1997019113 A3 WO 1997019113A3 CU 9600003 W CU9600003 W CU 9600003W WO 9719113 A3 WO9719113 A3 WO 9719113A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiidiotypic antibodies
monoclonal antiidiotypic
monoclonal
antibodies
immunostimulation
Prior art date
Application number
PCT/CU1996/000003
Other languages
English (en)
French (fr)
Other versions
WO1997019113A2 (es
Inventor
Abrahan Amparo Emilia Macias
Rodriguez Rolando Perez
Obaya Teresita Rodriguez
Zamora Mercedes Ramos
Lopez Gumersinda Bombino
Marichal Orlando Pena
Original Assignee
Ct De Inmunologia Molecular Ci
Abrahan Amparo Emilia Macias
Rodriguez Rolando Perez
Obaya Teresita Rodriguez
Zamora Mercedes Ramos
Lopez Gumersinda Bombino
Marichal Orlando Pena
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Inmunologia Molecular Ci, Abrahan Amparo Emilia Macias, Rodriguez Rolando Perez, Obaya Teresita Rodriguez, Zamora Mercedes Ramos, Lopez Gumersinda Bombino, Marichal Orlando Pena filed Critical Ct De Inmunologia Molecular Ci
Priority to EP96939804A priority Critical patent/EP0820472A1/en
Priority to AU76904/96A priority patent/AU719369B2/en
Priority to US08/875,706 priority patent/US6433148B1/en
Priority to JP9519266A priority patent/JPH11505131A/ja
Priority to BR9606978A priority patent/BR9606978A/pt
Priority to KR1019970704892A priority patent/KR19980701501A/ko
Publication of WO1997019113A2 publication Critical patent/WO1997019113A2/es
Publication of WO1997019113A3 publication Critical patent/WO1997019113A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Anticuerpos monoclonales antiidiotipos de tipo IgG relativos al sistema inmunitario, capaces de ejercer una interacción con los linfocitos T y B y tener un efecto inmunoregulador, una inmunoestimulación o inmunosupresión que pueden ser utilizados en la inmunoterapía de las enfermedades autoinmunes, infecciosas y cáncer.
PCT/CU1996/000003 1995-11-17 1996-11-18 Anticuerpos monoclonales antiidiotipos (ab2) y sus usos WO1997019113A2 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP96939804A EP0820472A1 (en) 1995-11-17 1996-11-18 Monoclonal antiidiotypic antibodies (ab2) and uses thereof
AU76904/96A AU719369B2 (en) 1995-11-17 1996-11-18 Monoclonal antiidiotypic antibodies (AB2) and their uses
US08/875,706 US6433148B1 (en) 1995-11-17 1996-11-18 Monoclonal anti-idiotypic antibodies (AB2) and their uses
JP9519266A JPH11505131A (ja) 1995-11-17 1996-11-18 単クローン抗イデイオタイプ抗体（ａｂ２）及びその使用
BR9606978A BR9606978A (pt) 1995-11-17 1996-11-18 Anticorpos monoclonais antiidiótipos (ab2) e usos dos mesmos
KR1019970704892A KR19980701501A (ko) 1995-11-17 1996-11-18 모노클로널 항치매 항체 및 그 사용

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU122/95 1995-11-17
CU1995122A CU22585A1 (es) 1995-11-17 1995-11-17 Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.

Publications (2)

Publication Number Publication Date
WO1997019113A2 WO1997019113A2 (es) 1997-05-29
WO1997019113A3 true WO1997019113A3 (es) 1997-09-25

Family

ID=5459408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU1996/000003 WO1997019113A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales antiidiotipos (ab2) y sus usos

Country Status (10)

Country Link
US (1) US6433148B1 (es)
EP (1) EP0820472A1 (es)
JP (1) JPH11505131A (es)
KR (1) KR19980701501A (es)
CN (1) CN1175958A (es)
AU (1) AU719369B2 (es)
BR (1) BR9606978A (es)
CA (1) CA2210705A1 (es)
CU (1) CU22585A1 (es)
WO (1) WO1997019113A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
WO2006102687A1 (en) * 2005-03-22 2006-09-28 The Trustees Of Columbia University In The City Of New York A liposome-based microarray and methods of use thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) * 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP2193145A4 (en) 2007-08-28 2011-05-18 Abbott Biotech Ltd COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB
US20110201022A1 (en) 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
EP4062928A3 (en) 2010-02-04 2022-11-30 BioMarin Pharmaceutical Inc. Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
JP6404821B2 (ja) * 2013-09-12 2018-10-17 国立大学法人 岡山大学 インターロイキン１０産生促進剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287226A1 (en) * 1987-03-23 1988-10-19 Hiver Limited Novel vaccines
WO1991004055A1 (en) * 1989-09-15 1991-04-04 Tanox Biosystems, Inc. Treatment of autoimmune disease
US5208146A (en) * 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
EP0657471A1 (en) * 1993-12-09 1995-06-14 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287226A1 (en) * 1987-03-23 1988-10-19 Hiver Limited Novel vaccines
WO1991004055A1 (en) * 1989-09-15 1991-04-04 Tanox Biosystems, Inc. Treatment of autoimmune disease
US5208146A (en) * 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
EP0657471A1 (en) * 1993-12-09 1995-06-14 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. ALFONSO: "E1, anti-GM2 ganglioside.", HYBRIDOMA, vol. 14, no. 1, February 1995 (1995-02-01), NEW YORK, NY, USA, pages 98, XP000647509 *

Also Published As

Publication number Publication date
EP0820472A1 (en) 1998-01-28
CA2210705A1 (en) 1997-05-29
KR19980701501A (ko) 1998-05-15
AU719369B2 (en) 2000-05-11
AU7690496A (en) 1997-06-11
MX9705444A (es) 1998-06-28
US6433148B1 (en) 2002-08-13
CU22585A1 (es) 1999-11-03
CN1175958A (zh) 1998-03-11
BR9606978A (pt) 1997-11-04
JPH11505131A (ja) 1999-05-18
WO1997019113A2 (es) 1997-05-29

Similar Documents

Publication Publication Date Title
Uchiyama et al. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells
GB9206422D0 (en) Antibody preparation
CA2267072A1 (en) Reconstituted human anti-hm1.24 antibody
CA2091769A1 (en) Framework mutated antibodies and their preparation
AU1866895A (en) Human monoclonal antibodies to herpes simplex virus and methods therefor
CA2182289A1 (en) Immuno-stimulatory monoclonal antibodies
EP0212403A3 (en) Monoclonal antibodies to mucin-like human differentiation antigens
CA2122613A1 (en) Targeted delivery of virus vector to mammalian cells
EP0568631A4 (en) MONOCLONAL ANTIBODIES FOR A CELL SURFACE RECEPTOR (ELAM-1) AND USES THEREOF.
PL330842A1 (en) Purified superficial sperm antigen, monoclonal antibody therefor and applications associated therewith
AU3045497A (en) Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag)
AU616156B2 (en) Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
WO1995029236A3 (en) Lymphocyte activation antigens and antibodies thereto
WO1997019113A3 (es) Anticuerpos monoclonales antiidiotipos (ab2) y sus usos
EP1161955A3 (en) Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells
AU6155896A (en) Humanized antibodies to e-selectin
AU2547995A (en) Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof
AU6496094A (en) Tumor-associated antigens recognized by t cells and the uses of these antigens
AU7796291A (en) High affinity antibodies to small peptides
GB2279076B (en) Antibodies to fungal antigens
FI954827A0 (fi) Monoklonaalisia anti-CD4-vasta-aineita kantavia immuunipartikkeleita ja niiden käyttö
EP0581108A3 (en) Bispecific antibody that reacts with sialyl-lea antigen and CD3.
Ruuth et al. Lymphokine-like activity of a strain of Mycoplasma arginini
AU5966596A (en) Antibodies to porcine cd34 positive cells and uses therefor
AU6777594A (en) Human monoclonal antibodies to human cytomegalovirus, and methods therefor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96192089.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP KR MX SG US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2210705

Country of ref document: CA

Ref document number: 2210705

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1997 519266

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/005444

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019970704892

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1996939804

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN JP KR MX SG US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 08875706

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1996939804

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996939804

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载